PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients

Immune checkpoint inhibitors that block the PD-1/PD-L1 signaling pathway have been used to treat a wide variety of cancers. Although results have been promising, significant inter-individual and inter-tumor variability has been observed. It is believed that better clinical outcome could be achieved...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei, Shen, Ge, Wu, Shikai, Song, Shiping, Ni, Yanli, Suo, Zhuoyao, Meng, Xiangying, Li, Dan, Zhou, Lin, Hao, Rimin, Zhao, Yaowei, Bai, Li, Hou, Lili, Liu, Bing, Liu, Guangxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584204/
https://www.ncbi.nlm.nih.gov/pubmed/28881603
http://dx.doi.org/10.18632/oncotarget.15006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584204/
https://www.ncbi.nlm.nih.gov/pubmed/28881603
http://dx.doi.org/10.18632/oncotarget.15006

Ejemplares similares